Update on the challenges and recent advances in cancer immunotherapy

References

• CrociDOSalatinoMTumor immune escape mechanisms that operate during metastasisCurr Pharm Biotechnol201112111923193621470132
   PubMed Web of Science ®Google Scholar
• MareelMConstantinoSEcosystems of invasion and metastasis in mammary morphogenesis and cancerInt J Dev Biol2011557–967168422161824
   PubMed Web of Science ®Google Scholar
• MacDonaldNChronic inflammatory states: their relationship to cancer prognosis and symptomsJ R Coll Physicians Edinb201141324625321949925
   PubMedGoogle Scholar
• GermainRNTumor immunologyBenaceraffBUnanueERTextbook of ImmunologyBaltimore, MDWilliams & Wilkins1979196217
   Google Scholar
• BarrettAJSavaniBNDoes chemotherapy modify the immune surveillance of hematological malignancies?Leukemia2009231535818830260
   PubMed Web of Science ®Google Scholar
• ShurinMRNaiditchHGutkinDWUmanskyVShurinGVChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agentsCurr Med Chem201219121792180322414087
   PubMed Web of Science ®Google Scholar
• WensveenFMvan GisbergenKPElderingEThe fourth dimension in immunological space: how the struggle for nutrients selects high-affinity lymphocytesImmunol Rev201224918410322889217
   PubMed Web of Science ®Google Scholar
• VossMJEntschladenFTumor interactions with soluble factors and the nervous systemCell Commun Signal201082120822525
   PubMed Web of Science ®Google Scholar
• ShiaoSLGanesanAPRugoHSCoussensLMImmune microenvironments in solid tumors: new targets for therapyGenes Dev201125242559257222190457
   PubMed Web of Science ®Google Scholar
• MellmanICoukosGDranoffGCancer immunotherapy comes of ageNature2011480737848048922193102
   PubMed Web of Science ®Google Scholar
• LeiboviciJItzhakiOHuszarMSinaiJThe tumor microenvironment: part 1Immunotherapy20113111367138422053887
   PubMed Web of Science ®Google Scholar
• LeiboviciJItzhakiOHuszarMSinaiJTargeting the tumor microenvironment by immunotherapy: part 2Immunotherapy20113111385140822053888
   PubMed Web of Science ®Google Scholar
• MartinFApetohLGhiringhelliFRole of myeloid-derived suppressor cells in tumor immunotherapyImmunotherapy201241435722150000
   PubMed Web of Science ®Google Scholar
• HaoNBLüMHFanYHCaoYLZhangZRYangSMMacrophages in tumor microenvironments and the progression of tumorsClin Dev Immunol2012201294809822778768
   PubMedGoogle Scholar
• FridlenderZGSunJKimSPolarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TANCancer Cell200916318319419732719
   PubMed Web of Science ®Google Scholar
• BianchiGBorgonovoGPistoiaVRaffaghelloLImmunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cellsHistol Histopathol201126794195121630223
   PubMed Web of Science ®Google Scholar
• ByrneWLMillsKHLedererJAO’SullivanGCTargeting regulatory T cells in cancerCancer Res201171226915692022068034
   PubMed Web of Science ®Google Scholar
• MunnDHBlocking IDO activity to enhance anti-tumor immunityFront Biosci (Elite Ed)2012473474522201909
   PubMedGoogle Scholar
• MarleauAMChenCSJoyceJATullisRHExosome removal as a therapeutic adjuvant in cancerJ Transl Med20121013422738135
   PubMed Web of Science ®Google Scholar
• MaYConfortiRAymericLL. How to improve the immunogenicity of chemotherapy and radiotherapyCancer Metastasis Rev2011301718221298323
   PubMed Web of Science ®Google Scholar
• RosentalBAppelMYYossefRHadadUBrusilovskyMPorgadorAThe effect of chemotherapy/radiotherapy on cancerous pattern recognition by NK cellsCurr Med Chem201219121780179122414084
   PubMed Web of Science ®Google Scholar
• BaronzioGGramagliaAFiorentiniGHyperthermia and immunity. A brief overviewIn Vivo2006206A68969517203747
   PubMed Web of Science ®Google Scholar
• ChangAERosenbergSAOverview of interleukin-2 as an immunotherapeutic agentSemin Surg Oncol1989563853902688029
   PubMedGoogle Scholar
• RosenbergSAThe development of new immunotherapies for the treatment of cancer using interleukin-2. A reviewAnn Surg198820821211353041925
   PubMed Web of Science ®Google Scholar
• TsungKNortonJALessons from Coley’s ToxinSurg Oncol2006151252816814541
   PubMed Web of Science ®Google Scholar
• WiemannBStarnesCOColey’s toxins, tumor necrosis factor and cancer research: a historical perspectivePharmacol Ther19946435295647724661
   PubMed Web of Science ®Google Scholar
• Rakoff-NahoumSMedzhitovRToll-like receptors and cancerNat Rev Cancer200991576319052556
   PubMed Web of Science ®Google Scholar
• LawsonKAMorrisDGOncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?Expert Opin Biol Ther201212789190322564154
   PubMed Web of Science ®Google Scholar
• PatyarSJoshiRByravDSPrakashAMedhiBDasBKBacteria in cancer therapy: a novel experimental strategyJ Biomed Sci20101712120331869
   PubMed Web of Science ®Google Scholar
• RestifoNPDudleyMERosenbergSAAdoptive immunotherapy for cancer: harnessing the T cell responseNat Rev Immunol201212426928122437939
   PubMed Web of Science ®Google Scholar
• KiesslingRKleinEWigzellH“Natural” killer cells in the mouse. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotypeEur J Immunol1975521121171234049
   PubMed Web of Science ®Google Scholar
• CaligiuriMAHuman natural killer cellsBlood2008112346146918650461
   PubMed Web of Science ®Google Scholar
• BironCAvan den ElsenPTuttMMMedveczkyPKumarVTerhorstCMurine natural killer cells stimulated in vivo do not express the T cell receptor alpha, beta, gamma, T3 delta, or T3 epsilon genesJ Immunol19871395170417103497976
   PubMed Web of Science ®Google Scholar
• RobertsonMJRitzJBiology and clinical relevance of human natural killer cellsBlood19907612242124382265240
   PubMed Web of Science ®Google Scholar
• KärreKLjunggrenHGPiontekGKiesslingRSelective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategyNature198631960556756783951539
   PubMed Web of Science ®Google Scholar
• LanierLLNatural killer cells: from no receptors to too manyImmunity1997643713789133416
   PubMed Web of Science ®Google Scholar
• LanierLLMissing self, NK cells, and the white albumJ Immunol200517411656515905491
   PubMed Web of Science ®Google Scholar
• GrimmEAMazumderAZhangHZRosenbergSALymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytesJ Exp Med19821556182318416176669
   PubMed Web of Science ®Google Scholar
• RosenbergSALotzeMTYangJCProspective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancerJ Natl Cancer Inst19938586226328468720
   PubMed Web of Science ®Google Scholar
• KammulaUSMarincolaFMCancer immunotherapy: is there real progress at last?BioDrugs199911424926018031135
   PubMed Web of Science ®Google Scholar
• RosenbergSAImmunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cellsImportant Adv Oncol19882172573042605
   PubMedGoogle Scholar
• KimuraHYamaguchiYAA phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinomaCancer199780142499210707
   PubMed Web of Science ®Google Scholar
• SangioloDCytokine induced killer cells as promising immunotherapy for solid tumorsJ Cancer2011236336821716717
   PubMed Web of Science ®Google Scholar
• WengDSZhouJZhouQMMinimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomasJ Immunother2008311637118157013
   PubMed Web of Science ®Google Scholar
• WuCJiangJShiLXuNProspective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancerAnticancer Res2008286B3997400219192663
   PubMed Web of Science ®Google Scholar
• ShiLZhouQWuJEfficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancerCancer Immunol Immunother201261122251225922674056
   PubMed Web of Science ®Google Scholar
• ShubinaIZhBliumenbergAGVolkovSMDemidovLVKiselevskiĭMVAdoptive immunotherapy of malignanciesVestn Ross Akad Med Nauk200711915 Russian18080522
   PubMedGoogle Scholar
• MorganRADudleyMEWunderlichJRCancer regression in patients after transfer of genetically engineered lymphocytesScience2006314579612612916946036
   PubMed Web of Science ®Google Scholar
• DoniaMEllebaekEAndersenMHStratenPSvaneIMAnalysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytesOncoimmunol20121812971304
   PubMed Web of Science ®Google Scholar
• ShiHLiuLWangZImproving the efficacy and safety of engineered T cell therapy for cancerCancer Lett2013328219119723022475
   PubMed Web of Science ®Google Scholar
• KellerRDendritic cells:their significance in health and diseaseImmunol Lett20017811312211578684
   PubMed Web of Science ®Google Scholar
• SallustoFNicoloCDe MariaRCorintiSTestiRCeramide inhibits antigen uptake and presentation by dendritic cellsJ Exp Med19961846241124168976196
   PubMed Web of Science ®Google Scholar
• HsuFJBenikeCFagnoniFVaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cellsNat Med19962152588564842
   PubMed Web of Science ®Google Scholar
• NestleFOAlijagicSGillietMVaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cellsNat Med1998433283329500607
   PubMed Web of Science ®Google Scholar
• RosenbergSAYangJCRestifoNPCancer immunotherapy: moving beyond current vaccinesNat Med200410990991515340416
   PubMed Web of Science ®Google Scholar
• OshitaCTakikawaMKumeADendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trialOncol Rep20122841131113822895835
   PubMed Web of Science ®Google Scholar
• EggermontAMTherapeutic vaccines in solid tumours: can they be harmful?Eur J Cancer200945122087209019477117
   PubMed Web of Science ®Google Scholar
• ChrvalaCAThe changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patientsP T201237845346323091338
   PubMedGoogle Scholar
• PloskerGLSipuleucel-T: in metastatic castration-resistant prostate cancerDrugs201171110110821175243
   PubMed Web of Science ®Google Scholar
• Di LorenzoGFerroMBuonerbaCSipuleucel-T (Provenge®) for castration-resistant prostate cancerBJU Int20121102 Pt 2E99E10422177289
   PubMed Web of Science ®Google Scholar
• CathelinDNicolasABouchotAFraszczakJLabbéJBonnotteBDendritic cell-tumor cell hybrids and immunotherapy: what’s next?Cytotherapy201113777478521299362
   PubMed Web of Science ®Google Scholar
• LiHWangCYuJDendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgeryCytotherapy20091181076108319929470
   PubMed Web of Science ®Google Scholar
• WestEJScottKJJenningsVAMelcherAAImmune activation by combination human lymphokine-activated killer and dendritic cell therapyBr J Cancer2011105678779521847125
   PubMed Web of Science ®Google Scholar
• AllenMLouise JonesJJekyll and Hyde: the role of the microenvironment on the progression of cancerJ Pathol2011223216217621125673
   PubMed Web of Science ®Google Scholar
• KhatamiMUnresolved inflammation: ‘immune tsunami’ or erosion of integrity in immune-privileged and immune-responsive tissues and acute and chronic inflammatory diseases or cancerExpert Opin Biol Ther201111111419143221663532
   PubMed Web of Science ®Google Scholar
• Ben-BaruchAInflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediatorsSemin Cancer Biol2006161385216139507
   PubMed Web of Science ®Google Scholar
• KalinskiPRegulation of immune responses by prostaglandin E2J Immunol20121881212822187483
   PubMed Web of Science ®Google Scholar
• Le BitouxMAStamenkovicITumor-host interactions: the role of inflammationHistochem Cell Biol200813061079109018953558
   PubMed Web of Science ®Google Scholar
• HariziHGualdeNPivotal role of PGE2 and IL-10 in the cross-regulation of dendritic cell-derived inflammatory mediatorsCell Mol Immunol20063427127716978535
   PubMed Web of Science ®Google Scholar
• SevkoAUmanskyVMyeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thievesJ Cancer20134131123386900
   PubMed Web of Science ®Google Scholar
• KaravitisJHixLMShiYHSchultzRFKhazaieKZhangMRegulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migrationPLoS One201279e4634223029485
   PubMed Web of Science ®Google Scholar
• SharmaSYangSCZhuLTumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancerCancer Res200565125211522015958566
   PubMed Web of Science ®Google Scholar
• ObermajerNMuthuswamyRLesnockJEdwardsRPKalinskiPPositive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cellsBlood2011118205498550521972293
   PubMed Web of Science ®Google Scholar
• VeltmanJDLambersMEvan NimwegenMCOX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC functionBMC Cancer20101046420804550
   PubMed Web of Science ®Google Scholar
• DesserLHolomanovaDZavadovaEPavelkaKMohrTHerbacekIOral therapy with proteolytic enzymes decreases excessive TGF-beta levels in human bloodCancer Chemother Pharmacol200147SupplS10S1511561866
   PubMed Web of Science ®Google Scholar
• SrivastavaMKAnderssonÅZhuLMyeloid suppressor cells and immune modulation in lung cancerImmunotherapy20124329130422401635
   PubMed Web of Science ®Google Scholar
• PastułaAMarcinkiewiczJMyeloid-derived suppressor cells: a double-edged sword?Int J Exp Pathol2011922737821314739
   PubMed Web of Science ®Google Scholar
• NagarajSGabrilovichDIMyeloid-derived suppressor cells in human cancerCancer J201016434835320693846
   PubMed Web of Science ®Google Scholar
• GretenTFMannsMPKorangyFMyeloid derived suppressor cells in human diseasesInt Immunopharmacol201111780280721237299
   PubMed Web of Science ®Google Scholar
• ChalminFMignotGGhiringhelliFMyeloid-derived suppressor cells: a key player in cancerMed Sci (Paris)2010266–757657920619155
   PubMed Web of Science ®Google Scholar
• FilipazziPHuberVRivoltiniLPhenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patientsCancer Immunol Immunother201261225526322120756
   PubMed Web of Science ®Google Scholar
• KaoJKoECEisensteinSTargeting immune suppressing myeloid-derived suppressor cells in oncologyCrit Rev Oncol Hematol2011771121920304669
   PubMed Web of Science ®Google Scholar
• NaiditchHShurinMRShurinGVTargeting myeloid regulatory cells in cancer by chemotherapeutic agentsImmunol Res2011502–327628521717082
   PubMed Web of Science ®Google Scholar
• DjeuJWeiSChemoimmunomodulation of MDSCs as a novel strategy for cancer therapyOncoimmunology20121112112222720231
   PubMed Web of Science ®Google Scholar
• GhiringhelliFRebeCHichamiADelmasDImmunomodulation and anti-inflammatory roles of polyphenols as anticancer agentsAnticancer Agents Med Chem201212885287322292769
   PubMed Web of Science ®Google Scholar
• KoJSZeaAHRiniBISunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patientsClin Cancer Res20091562148215719276286
   PubMed Web of Science ®Google Scholar
• TonguMHarashimaNMonmaHMetronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivoCancer Immunol Immunother201362238339122926062
   PubMed Web of Science ®Google Scholar
• LathersDMClarkJIAchilleNJYoungMRPhase IB study of 25-hydroxyvitamin D(3) treatment to diminish suppressor cells in head and neck cancer patientsHum Immunol200162111282129311704292
   PubMed Web of Science ®Google Scholar
• MirzaNFishmanMFrickeIAll-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patientsCancer Res200666189299930716982775
   PubMed Web of Science ®Google Scholar
• ApetohLVégranFLadoireSGhiringhelliFRestoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapiesCurr Mol Med201111536537221568934
   PubMed Web of Science ®Google Scholar
• van CruijsenHHoekmanKStamAGDefective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptorClin Dev Immunol200720071731518320010
   PubMedGoogle Scholar
• UgelSDelpozzoFDesantisGTherapeutic targeting of myeloid-derived suppressor cellsCurr Opin Pharmacol20099447048119616475
   PubMed Web of Science ®Google Scholar
• FacciabeneAMotzGTCoukosGT-regulatory cells: key players in tumor immune escape and angiogenesisCancer Res20127292162217122549946
   PubMed Web of Science ®Google Scholar
• WilkeCMWuKZhaoEWangGZouWPrognostic significance of regulatory T cells in tumorInt J Cancer2010127474875820473951
   PubMed Web of Science ®Google Scholar
• ZouWRegulatory T cells, tumour immunity and immunotherapyNat Rev Immunol20066429530716557261
   PubMed Web of Science ®Google Scholar
• GhiringhelliFMenardCPuigPEMetronomic cyclophosphamide regimen electively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunol Immunother200756564164816960692
   PubMed Web of Science ®Google Scholar
• CoolsNPonsaertsPVan TendelooVFBernemanZNRegulatory T cells and human diseaseClin Dev Immunol200720078919518317534
   PubMedGoogle Scholar
• MuranskiPBoniAWrzesinskiCIncreased intensity lymphodepletion and adoptive immunotherapy – how far can we go?Nat Clin Pract Oncol200631266868117139318
   PubMedGoogle Scholar
• GrazianiGTentoriLNavarraPIpilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancerPharmacol Res201265192221930211
   PubMed Web of Science ®Google Scholar
• PereHTanchotCBayryJComprehensive analysis of current approaches to inhibit regulatory T cells in cancerOncoimmunology20121332633322737608
   PubMed Web of Science ®Google Scholar
• YaqubSHenjumKMahicMRegulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent mannerCancer Immunol Immunother200857681382117962941
   PubMed Web of Science ®Google Scholar
• MandapathilMSzczepanskiMJSzajnikMAdenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cellsJ Biol Chem201028536275712758020558731
   PubMed Web of Science ®Google Scholar
• DienstmannRMarkmanBTaberneroJApplication of monoclonal antibodies as cancer therapy in solid tumorsCurr Clin Pharmacol20127213714522432839
   PubMedGoogle Scholar
• LipsonEJDrakeCGIpilimumab: an anti-CTLA-4 antibody for metastatic melanomaClin Cancer Res201117226958696221900389
   PubMed Web of Science ®Google Scholar
• SinghNMadanRAGulleyJLIpilimumab in prostate cancerExpert Opin Biol Ther201313230331323265575
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• MargolinKIpilimumab in a Phase II trial of melanoma patients with brain metastasesOncoimmunology2012171197119923170278
   PubMed Web of Science ®Google Scholar
• KhattakMAFisherRHughesPGoreMLarkinJIpilimumab activity in advanced uveal melanomaMelanoma Res2013231798123211837
   PubMed Web of Science ®Google Scholar
• GerritsenWRThe evolving role of immunotherapy in prostate cancerAnn Oncol201223Suppl 8viii22viii2722918924
   PubMed Web of Science ®Google Scholar
• ReckMBondarenkoILuftAIpilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trialAnn Oncol2013241758322858559
   PubMed Web of Science ®Google Scholar
• FellnerCIpilimumab (Yervoy) Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its useP T201237950351123066344
   PubMedGoogle Scholar
• BakacsTMehrishiJNMossRWIpilimumab (Yervoy) and the TGN1412 catastropheImmunobiology2012217658358921821307
   PubMed Web of Science ®Google Scholar
• ThurberGMSchmidtMMWittrupKDFactors determining antibody distribution in tumorsTrends Pharmacol Sci2008292576118179828
   PubMed Web of Science ®Google Scholar
• ReubenJMLeeBNLiCBiologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanomaCancer2006106112437244416615096
   PubMed Web of Science ®Google Scholar
• TopalianSLDrakeCGPardollDMTargeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunityCurr Opin Immunol201224220721222236695
   PubMed Web of Science ®Google Scholar
• OkazakiTHonjoTPD-1 and PD-1 ligands: from discovery to clinical applicationInt Immunol200719781382417606980
   PubMed Web of Science ®Google Scholar
• ZitvogelLKroemerGTargeting PD-1/PD-L1 interactions for cancer immunotherapyOncoimmunology2012181223122523243584
   PubMed Web of Science ®Google Scholar
• Ménétrier-CauxCCurielTFagetJManuelMCauxCZouWTargeting regulatory T cellsTarget Oncol201271152822327882
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• TangPAHengDYProgrammed Death 1 Pathway inhibition in Metastatic Renal Cell Cancer and Prostate CancerCurr Oncol Rep20131529810423263823
   PubMed Web of Science ®Google Scholar
• CurranMAMontalvoWYagitaHAllisonJPPD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProc Natl Acad Sci USA201010794275428020160101
   PubMed Web of Science ®Google Scholar
• ZhangHGGrizzleWEExosomes and cancer: a newly described pathway of immune suppressionClin Cancer Res201117595996421224375
   PubMed Web of Science ®Google Scholar
• CamussiGDeregibusMCBrunoSGrangeCFonsatoVTettaCExosome/microvesicle-mediated epigenetic reprogramming of cellsAm J Cancer Res2011119811021969178
   PubMed Web of Science ®Google Scholar
• IeroMValentiRHuberVTumour-released exosomes and their implications in cancer immunityCell Death Differ2008151808817932500
   PubMed Web of Science ®Google Scholar
• LentzMRContinuous whole blood UltraPheresis procedure in patients with metastatic cancerJ Biol Response Mod1989855115272795094
   PubMedGoogle Scholar